News for Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences' TYRA-300 shows promise as an FGFR3 inhibitor with fewer side effects, but mixed market reactions spotlight FGFR1/2 concerns. See more here.

On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) made a significant move by reducing its holdings in Tyra Biosciences Inc by 717,000 share

PR NewswireCARLSBAD, Calif., Jan. 10, 2025 -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC--First patie

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Thursday. Shares of Neumora Therapeutics, Inc. NMRA fell shar...

Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg.

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences director Nina S. Kjellson sells shares worth $194k

On October 30, 2024, Alan Fuhrman, Chief Financial Officer of Tyra Biosciences Inc (TYRA), purchased 9,500 shares of the company, as reported in a recent SEC Fi

Tyra Biosciences director Nina Kjellson sells $2.28m in stock

FDA clears Tyra Biosciences' trial for dwarfism drug

Hong Kong-based CCSC Technology International Holdings Limited (CCTG) is up over 64 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences names Doug Warner as new Chief Medical Officer

Tyra Biosciences is a speculative play with potential for growth despite lack of revenue, focusing on precision medicines in oncology. See why TYRA is hold rated.

Bladder cancer, marked by abnormal cell growth in the bladder lining, presents a global health concern. The incidence of bladder cancer is on the rise due...

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.

US stocks traded higher this morning, with the NASDAQ gaining more than 230 points on Thursday. Following the market opening Thursday, the Dow traded up 0.02% to 34,092.96, while the NASDAQ rose 2.00% to 11,816.32. The S&P 500 also rose, gaining 1.05% to 4,119.21. Leading and Lagging Sectors

Read Investment Analysts’ Downgrades for May 31st (AAP, AEO, ANIOY, BKEAY, CECE, CLLNY, CQP, EPOKY, ESS, EXK) at ETF Daily News